Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Guides / Retatrutide

Retatrutide side effects: what the trials reported

The adverse events the published trials recorded, how often, and what a trial cannot tell you about safety.

5 min read · 2026-11-17

The most common: stomach and gut

Across the phase 1b trial, the phase 2 obesity trial and the phase 3 diabetes trial, gastrointestinal events were the most frequent adverse events 145.

In the phase 2 diabetes trial, mild-to-moderate gastrointestinal events, including nausea, diarrhea, vomiting and constipation, were reported by 67 (35%) of the 190 participants on retatrutide, against six (13%) of 45 on placebo and 16 (35%) of 46 on dulaglutide. There were no reports of severe hypoglycemia and no deaths in that trial 2.

In the phase 2 obesity trial these events were dose related and mostly mild to moderate. They were partly eased in the arms whose first dose was 2 mg rather than 4 mg 1.

Heart rate

In the phase 2 obesity trial, heart rate rose in a dose-dependent way, peaked at 24 weeks and declined after that 1.

What the phase 3 trial added

In TRANSCEND-T2D-1 the most frequent adverse events with retatrutide were again generally mild to moderate gastrointestinal events, which the authors report subsided over time. Between 2% and 5% of participants on retatrutide stopped the study treatment because of adverse events, against 0% on placebo 4.

Two deaths occurred during the study, both in the 4 mg group. The paper reports both as unrelated to the study drug 4.

What a trial cannot tell you

Trial participants are screened: people with many conditions are excluded before a trial starts, and everyone in it is monitored. The longest published trial ran 48 weeks 1. Rare harms and harms that take years to appear are found in larger and longer studies, which is one reason a regulator reviews a whole program before licensing anything.

Material sold for research is not the trial's medicine: it is not made, tested or dosed to that standard. Nothing here is advice. Anyone with symptoms, or thinking about any treatment, should speak to a medical professional.

Sources

The numbers are those of the Retatrutide page, where every source is listed.

  1. 1Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England Journal of Medicine, 2023
  2. 2Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet, 2023
  3. 4Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet, 2026
  4. 5Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet, 2022
The full Retatrutide page

Read next